Revenue Growth Of 15% Highlights Metropolis Healthcare’s Steady Momentum In Diagnostics

Metropolis Healthcare Limited has announced its Q3 FY25 results, showcasing consistent growth in revenue and profitability. The company’s focus on strengthening its consumer segment, expanding specialty diagnostics, and enhancing patient engagement has contributed to its strong quarterly performance.

Key Highlights

• Standalone revenue grew 15% YoY, reflecting resilient demand across diagnostic services.
• Consolidated revenue from operations stood at approximately ₹323 crore, marking a 10.9% YoY increase.
• Profit after tax rose 15.3% YoY to ₹31 crore, supported by operational efficiency.
• EBITDA reached ₹72 crore, up 9.4% YoY, with margins at 22.2%.
• B2C segment contributed 55% of total revenue, up from 53% last year, driven by higher test volumes and revenue per patient.
• Specialty tests and TruHealth packages showed strong traction, with TruHealth revenue rising 25% YoY to ₹55 crore.
• Expansion into tier II and III cities boosted patient engagement and doctor coverage.

Broader Context
Metropolis Healthcare’s steady growth underscores its ability to balance expansion with profitability. By strengthening consumer-focused offerings and specialty diagnostics, the company is well-positioned to sustain momentum in India’s competitive healthcare diagnostics sector.

Sources: Business Standard, Sukhanidhi Research